This company has been marked as potentially delisted and may not be actively trading. NASDAQ:STDY SteadyMed (STDY) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About SteadyMed Stock (NASDAQ:STDY) 30 days 90 days 365 days Advanced Chart Get SteadyMed alerts:Sign Up Key Stats Today's Range$4.73▼$4.7350-Day Range N/A52-Week Range$2.60▼$6.45Volume160 shsAverage Volume85,138 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and high-value diseases with unmet parenteral delivery needs. The company's product candidates are enabled by its proprietary PatchPump, a discreet, water-resistant, and disposable drug administration technology. Its lead drug product candidate is Trevyent that is used for treating pulmonary arterial hypertension. The company also develops two drug product candidates for the treatment of post-surgical and acute pain in the home setting. It has operations in Israel, the United States, and Europe. SteadyMed Ltd. was founded in 2005 and is headquartered in San Ramon, California. Read More Receive STDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SteadyMed and its competitors with MarketBeat's FREE daily newsletter. Email Address STDY Stock News HeadlinesApes may remember old friends and family decades later, study saysDecember 20, 2023 | washingtonpost.comSocial media effect 'tiny' in teenagers, large study findsDecember 18, 2023 | bbc.comB[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to two crypto experts, that moment is here. Their Crypto Code Workshop shows how to get positioned before altcoins take off, ride the wave, and lock in gains — with a free $10 Bitcoin bonus just for attending.July 16 at 2:00 AM | Crypto Swap Profits (Ad)Should we clean up the trash in our oceans? New study has a controversial answer.November 14, 2023 | usatoday.com'Climate captives': Frogs, salamanders and toads dying rapidly as Earth warms, study saysOctober 24, 2023 | usatoday.comFluoride And IQ? What Is The Link, What This Study SaysOctober 3, 2023 | forbes.comBabies, young child exposed to more screen time linked with developmental delays: StudySeptember 3, 2023 | foxnews.comCost of Owning a Dog in Every State (2023 Study)August 28, 2023 | marketwatch.comSee More Headlines STDY Stock Analysis - Frequently Asked Questions How were SteadyMed's earnings last quarter? SteadyMed Ltd. (NASDAQ:STDY) posted its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.17. When did SteadyMed IPO? SteadyMed (STDY) raised $56 million in an IPO on Friday, March 20th 2015. The company issued 4,300,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager. What other stocks do shareholders of SteadyMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that SteadyMed investors own include Amicus Therapeutics (FOLD), Protalix BioTherapeutics (PLX), Fate Therapeutics (FATE), Madrigal Pharmaceuticals (MDGL), Neurocrine Biosciences (NBIX), Rigel Pharmaceuticals (RIGL) and Sophiris Bio (SPHS). Company Calendar Last Earnings8/14/2018Today7/16/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:STDY CIK1619087 Webwww.steadymed.com Phone925-272-4999FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:STDY) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett’s Little-Known Succession PlanYou could miss out on millions buying a house - even if prices rise Joel Litman is a millionaire member of ...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SteadyMed Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SteadyMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.